Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 2:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Rhinitis, Allergic Clear all
Completed Phase 4 Interventional Results available

A Study Evaluating the Efficacy and Impact on Health-related Quality of Life of Levocetirizine in Adults With Seasonal Allergic Rhinitis

NCT00621959
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
levocetirizine dihydrochloride, placebo
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years to 65 Years
Enrollment
596 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
26
States / cities
Scottsdale, Arizona • Hot Springs, Arkansas • Little Rock, Arkansas + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2020 · Synced Jul 22, 2026, 2:04 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Seasonal Allergic Rhinitis (SAR)

NCT02631551
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
GSP 301 NS, Olopatadine HCl NS, Mometasone furoate NS, GSP 301 Placebo NS
Drug
Lead sponsor
Glenmark Specialty S.A.
Industry
Eligibility
12 Years and older
Enrollment
1,180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
37
States / cities
Mission Viejo, California • San Diego, California • San Jose, California + 28 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2018 · Synced Jul 22, 2026, 2:04 AM EDT
Terminated Phase 1 Interventional

Safety Study of 20,000 EU of Clinical Center Reference Endotoxin in Allergic Adults With and Without Mild Asthma

NCT00630461
View directory record Official record
Conditions
Mild Allergic Rhinitis, Mild Allergic Rhinitis With Mild Asthma
Interventions
Clinical Center Reference Endotoxin
Biological
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 50 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 7, 2012 · Synced Jul 22, 2026, 2:04 AM EDT
Not listed Phase 4 Interventional

Comparative Study of Sinol and Sinol-M in Patients With Congestion Due to Allergic Rhinitis

NCT00825656
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Sinol or Sinol-M nasal spray
Drug
Lead sponsor
Strategic Biosciences
Industry
Eligibility
12 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Wheaton, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 22, 2009 · Synced Jul 22, 2026, 2:04 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of a Novel Questionnaire to Assess Patient Satisfaction With and Preference of Intranasal Corticosteroids for the Treatment of Allergic Rhinitis

NCT01287364
View directory record Official record
Conditions
Perennial Allergic Rhinitis
Interventions
ciclesonide hydrofluoroalkane (HFA) nasal aerosol, mometasone nasal inhalation
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
6
States / cities
Mission Viejo, California • San Diego, California • North Dartmouth, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2012 · Synced Jul 22, 2026, 2:04 AM EDT
Completed Not applicable Interventional Results available

Efficacy of Esomeprazole for Non-Allergic Rhinitis: A Double-blind, Placebo Controlled Trial

NCT00745849
View directory record Official record
Conditions
Vasomotor Rhinitis
Interventions
esomeprazole, placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 10, 2019 · Synced Jul 22, 2026, 2:04 AM EDT
Not listed No phase listed Observational

Effect of Montelukast on Basophils, In-vitro

NCT00710450
View directory record Official record
Conditions
Allergic Asthma, Allergic Rhinitis
Interventions
Not listed
Lead sponsor
Creighton University
Other
Eligibility
12 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 22, 2011 · Synced Jul 22, 2026, 2:04 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Two Nasal Sprays to Treat Seasonal Allergies

NCT00720278
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
0.15% azelastine hydrochloride 1644 mcg daily, 0.1% azelastine hydrochloride 1096 mcg daily, Placebo
Drug
Lead sponsor
Meda Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
526 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
29
States / cities
Oxford, Alabama • Encinitas, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2010 · Synced Jul 22, 2026, 2:04 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Examine the Efficacy and Safety of Anti-Fel d 1 Antibodies Injections in Cat-allergic Adolescent and Adult Patients With Allergic Rhinitis Who Live With a Cat

NCT04981717
View directory record Official record
Conditions
Allergic Rhinitis Due to Cat Allergy
Interventions
REGN1908-1909, Matching Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
446 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
42
States / cities
Mission Viejo, California • Riverside, California • Rolling Hills Estates, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2024 · Synced Jul 22, 2026, 2:04 AM EDT
Completed Phase 3 Interventional Results available

Study of the Effects of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol on Hypothalamic-Pituitary-Adrenal (HPA) Axis

NCT01033825
View directory record Official record
Conditions
Perennial Allergic Rhinitis
Interventions
Ciclesonide HFA Nasal Aerosol 320 mcg, Ciclesonide HFA Nasal Aerosol 160 mcg, HFA Nasal Aerosol placebo, Ciclesonide Aqueous Nasal Spray 200 mcg, AQ Nasal Spray Placebo, Placebo plus Dexamethasone HFA, Placebo AQ plus Dexamethasone 6 mg
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
6
States / cities
Stockbridge, Georgia • North Dartmouth, Massachusetts • Minneappolis, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2012 · Synced Jul 22, 2026, 2:04 AM EDT
Completed Phase 3 Interventional Results available

Study in Adult and Adolescent Subjects With PAR (Perennial Allergic Rhinitis)

NCT01134705
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial
Interventions
Beclomethasone dipropionate hydrofluoroalkane HFA Nasal Aerosol, Placebo Nasal Aerosol
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
35
States / cities
Los Angeles, California • Mission Viejo, California • San Diego, California + 30 more
Source: ClinicalTrials.gov public record
Updated May 22, 2012 · Synced Jul 22, 2026, 2:04 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Olopatadine HCl Nasal Spray in 6-11 Year Old Patients

NCT00578929
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Olopatadine Hydrochloride Nasal Spray 0.6%, Vehicle
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
6 Years to 11 Years
Enrollment
2,388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Kenilworth, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 1, 2010 · Synced Jul 22, 2026, 2:04 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Levocetirizine Effect on Nasal Nitric Oxide and Nasal Eosinophils in Subjects With Perennial Allergic Rhinitis

NCT00894231
View directory record Official record
Conditions
Perennial Allergic Rhinitis
Interventions
levocetirizine (Xyzal), placebo
Drug
Lead sponsor
AAADRS Clinical Research Center
Other
Eligibility
12 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Sep 3, 2009 · Synced Jul 22, 2026, 2:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of a 10,000 EU Dose of Endotoxin in Allergic and Mildly Asthmatic Adults

NCT00839189
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial, Rhinitis, Allergic, Seasonal, Asthma
Interventions
Clinical Center Reference Endotoxin (CCRE)
Biological
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 50 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2006
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 8, 2009 · Synced Jul 22, 2026, 2:04 AM EDT
Completed No phase listed Observational

Effectiveness of Beclomethasone Dipropionate Nasal Aerosol for Perennial Allergic Rhinitis

NCT01632540
View directory record Official record
Conditions
Perennial Allergic Rhinitis (PAR)
Interventions
Beclomethasone Dipropionate (BDP) Nasal Aerosol
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
824 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
46
States / cities
Little Rock, Alaska • Phoenix, Arizona • Encinitas, California + 39 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2014 · Synced Jul 22, 2026, 2:04 AM EDT
Completed Phase 2 Interventional

A Study of Epinastine Nasal Spray in Subjects With Seasonal Allergic Rhinitis

NCT00407927
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Epinastine Nasal Spray
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
12 Years and older
Enrollment
571 participants
Timeline
2006 – 2007
U.S. locations
7
States / cities
Austin, Texas • Kerrville, Texas • New Braunfels, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2015 · Synced Jul 22, 2026, 2:04 AM EDT
Completed Phase 2 Interventional

The Effect of Nasal Carbon Dioxide (CO2) Used As-Needed in the Symptomatic Treatment of Seasonal Allergic Rhinitis

NCT00917020
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Nasal CO2, Inactive Placebo Gas
Drug
Lead sponsor
Capnia, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 14, 2012 · Synced Jul 22, 2026, 2:04 AM EDT
Completed Phase 4 Interventional Results available

Safety of Astepro 0.15% Nasal Spray and Astepro 0.1% Nasal Spray in Children Ages >6 Months to <6 Years With AR

NCT01880840
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
205.5 mcg of azelastine hydrochloride, 137 mcg of azelastine hydrochloride
Drug
Lead sponsor
Meda Pharmaceuticals
Industry
Eligibility
6 Months to 5 Years
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
14
States / cities
Birmingham, Alabama • Little Rock, Alaska • Costa Mesa, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2015 · Synced Jul 22, 2026, 2:04 AM EDT
Completed Phase 3 Interventional Results available

Hypothalamic-Pituitary-Adrenal (HPA)-Axis Study in Pediatric Subjects With Perennial Allergic Rhinitis (PAR)

NCT01697956
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
BDP, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
6 Years to 11 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
6
States / cities
Long Beach, California • Stockbridge, Georgia • Plymouth, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2015 · Synced Jul 22, 2026, 2:04 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Bepotastine Besilate Nasal Spray in the Treatment of Seasonal Allergic Rhinitis

NCT01277341
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Bepotastine Besilate Nasal Spray 2% Twice a day, Bepotastine Besilate Nasal Spray 3% Twice a day, Bepotastine Besilate Nasal Spray 4% Twice a day, Placebo Nasal Spray
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
12 Years and older
Enrollment
601 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Oct 4, 2020 · Synced Jul 22, 2026, 2:04 AM EDT
Terminated Phase 2 Interventional

Treatment of Ragweed-Allergic Asthma With an Immunostimulatory Drug

NCT00318747
View directory record Official record
Conditions
Asthma, Allergy, Allergic Rhinitis, Rhinitis, Allergic, Seasonal
Interventions
Amb a 1-immunostimulatory oligodeoxyribonucleotide conjugate (AIC)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
4
States / cities
Baltimore, Maryland • Cincinnati, Ohio • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Jul 22, 2026, 2:04 AM EDT
Completed No phase listed Observational

Effects of Long-Term Treatment With Nasally Inhaled Triamcinolone Acetonide in Children With Allergic Rhinitis

NCT00189449
View directory record Official record
Conditions
Allergic Rhinitis, Allergy, Growth
Interventions
Not listed
Lead sponsor
West Penn Allegheny Health System
Other
Eligibility
6 Years to 13 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2007
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 30, 2008 · Synced Jul 22, 2026, 2:04 AM EDT
Not listed Phase 3 Interventional

Clinical Equivalence of Azelastine Hydrochloride and Fluticasone Propionate, 137/50 mcg Nasal Spray to Dymista™

NCT02249663
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Azelastine hydrochloride and Fluticasone propionate, Dymista™, Placebo
Drug · Other
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
12 Years and older
Enrollment
1,535 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 24, 2014 · Synced Jul 22, 2026, 2:04 AM EDT
Completed Phase 3 Interventional Results available

Mite Asthma Pediatric Immunotherapy Trial

NCT03654976
View directory record Official record
Conditions
Allergic Asthma Due to Dermatophagoides Farinae, Allergic Asthma Due to Dermatophagoides Pteronyssinus, Allergic Rhinitis Due to House Dust Mite
Interventions
HDM SLIT-tablet, Placebo
Biological · Other
Lead sponsor
ALK-Abelló A/S
Industry
Eligibility
5 Years to 17 Years
Enrollment
533 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
7
States / cities
Miami, Florida • Columbus, Georgia • Ypsilanti, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2023 · Synced Jul 22, 2026, 2:04 AM EDT